Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

Asmita Shukla, Seongho Kim, Hyejeong Jang, Andrew Kin, Aasiya Matin, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph Uberti, Dipenkumar Modi

Blood (2023) 142 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2023-190562

Published: 2023

Journal Articles

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Dipenkumar Modi, Maya Shatta, Seongho Kim, Abhinav Deol, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti

Blood (2022) 140 (Supplement 1): 694–695.

https://doi.org/10.1182/blood-2022-166536

Published: 2022

Journal Articles

Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?

Abdul Moiz Khan, Neha Venkatesh, Joseph P. Uberti, Voravit Ratanatharathorn, Dipenkumar Modi, Lois Ayash, Asif Alavi, Andrew Kin, Aasiya Matin, Abhinav Deol

Blood (2022) 140 (Supplement 1): 7565–7566.

https://doi.org/10.1182/blood-2022-164618

Published: 2022

Journal Articles

Incidence, Risk Factors and Outcomes of Pancytopenia Following Chimeric Antigen Receptor (CAR)-T Cell Therapy in Relapsed Refractory Diffuse Large B Cell Lymphoma

Malini Surapaneni, Samer Alkassis, Seongho Kim, Abhinav Deol, Lois Ayash, Asif Alavi, Andrew Kin, Voravit Ratanatharathorn, Joseph P. Uberti, Dipenkumar Modi

Blood (2021) 138 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2021-148961

Published: 2021

Journal Articles

Feasibility of Outpatient CAR T Cell Therapy: Experience of a Single Institution

Yusra F Shao, Dipenkumar Modi, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti, Abhinav Deol

Blood (2021) 138 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2021-146283

Published: 2021

Journal Articles

Outcome of Severe Aplastic Anemia Post Allogenic Stem Cell Transplant with Mycophenolate and Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis

Omar Albanyan, Hyejeong Jang, Seongho Kim, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Dipenkumar Modi, Joseph P. Uberti, Abhinav Deol

Blood (2021) 138 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2021-144995

Published: 2021

Journal Articles

Impact of Pre-Transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission

Omar Albanyan, MD, Samer Alkassis, Seongho Kim, PhD, Andrew Kin, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Dipenkumar Modi, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140079

Published: 2020

Journal Articles

Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide

Omar Albanyan, MD, Seongho Kim, PhD, Anupama Kottam, MD, Abhinav Deol, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Dipenkumar Modi, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141416

Published: 2020

Journal Articles

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Relapse-Free and Overall Survival

Dipenkumar Modi, MD, Vijendra Singh, MD, Seongho Kim, PhD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2019) 134 (Supplement_1): 4488.

https://doi.org/10.1182/blood-2019-125418

Published: 2019

Journal Articles

Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Dipenkumar Modi, MD, Malini Surapaneni, MD, Seongho Kim, PhD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 4527.

https://doi.org/10.1182/blood-2019-125437

Published: 2019

Journal Articles

Can Peri-Transplant Radiation Therapy Improve Outcomes of Autologous Stem Cell Transplant in Hodgkin Lymphoma?

Harsh Shah, DO, Paramveer Singh, MD, Jorgena Kosti, DO, Hyejeong Jang, Seongho Kim, PhD, Andrew Kin, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 5702.

https://doi.org/10.1182/blood-2019-124931

Published: 2019

Journal Articles

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Dipenkumar Modi, MD, Seongho Kim, PhD, Jie Chi, MD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 3311.

https://doi.org/10.1182/blood-2019-124838

Published: 2019

Journal Articles

Post-ASCT Outcomes in Multiple Myeloma Patients Who Underwent ASCT with G-CSF+Plerixafor Versus G-CSF Mobilized Graft

Harsh Shah, DO, Seongho Kim, PhD, Paramveer Singh, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2018-99-113713

Published: 2018

Journal Articles

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Nadine Abdallah, MD, Seongho Kim, PhD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2018-99-118400

Published: 2018

Journal Articles

Long-Term Outcomes of Allogeneic Stem Cell Transplant in Peripheral T-Cell Lymphoma

Dipenkumar Modi, MD, Seongho Kim, PhD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2018) 132 (Supplement 1): 4672.

https://doi.org/10.1182/blood-2018-99-114288

Published: 2018

Journal Articles

Long Term Outcomes of Allogeneic Transplant in Diffuse Large B-Cell Lymphoma

Dipenkumar Modi, MD, Seongho Kim, PhD, Malini Surapaneni, MD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2018) 132 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2018-99-114278

Published: 2018

Journal Articles

Pre-Transplant Hypomethylating Agents Do Not Influence Post-Transplant Outcomes in Myelodysplastic Syndrome

Dipenkumar Modi, MD, Seongho Kim, PhD, Vijendra Singh, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 3102.

https://doi.org/10.1182/blood-2018-99-114256

Published: 2018

Journal Articles

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Dipenkumar Modi, MD, Wei Chen, Hyejeong Jang, Abhinav Deol, MD, Lois Ayash, MD, Asif Alavi, MD, Divaya Bhutani, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2017) 130 (Supplement 1): 3275.

https://doi.org/10.1182/blood.V130.Suppl_1.3275.3275

Published: 2017

Journal Articles

Post Autologous Stem Cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/ VGPR after Induction Therapy

Naresh Bumma, MD, Monica Peravali, MD, Jayadev Mettu, MD, Ghayathri Jeyakumar, MD, Seongho Kim, PhD, Divaya Bhutani, MD, Abhinav Deol, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Asif Alavi, MD

Blood (2017) 130 (Supplement 1): 5518.

https://doi.org/10.1182/blood.V130.Suppl_1.5518.5518

Published: 2017

Journal Articles

Comparison of Outcomes of Post-Transplant Cyclophosphamide between Haplo-Identical and Matched/Mismatched Donor Peripheral Blood Stem Cell Transplantation

Dipenkumar Modi, MD, Seongho Kim, PhD, Abhinav Deol, MD, Lois Ayash, MD, Asif Alavi, MD, Divaya Bhutani, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2017) 130 (Supplement 1): 2034.

https://doi.org/10.1182/blood.V130.Suppl_1.2034.2034

Published: 2017

NARROW

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?

Incidence, Risk Factors and Outcomes of Pancytopenia Following Chimeric Antigen Receptor (CAR)-T Cell Therapy in Relapsed Refractory Diffuse Large B Cell Lymphoma

Feasibility of Outpatient CAR T Cell Therapy: Experience of a Single Institution

Outcome of Severe Aplastic Anemia Post Allogenic Stem Cell Transplant with Mycophenolate and Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis

Impact of Pre-Transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission

Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Relapse-Free and Overall Survival

Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Can Peri-Transplant Radiation Therapy Improve Outcomes of Autologous Stem Cell Transplant in Hodgkin Lymphoma?

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Post-ASCT Outcomes in Multiple Myeloma Patients Who Underwent ASCT with G-CSF+Plerixafor Versus G-CSF Mobilized Graft

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Long-Term Outcomes of Allogeneic Stem Cell Transplant in Peripheral T-Cell Lymphoma

Long Term Outcomes of Allogeneic Transplant in Diffuse Large B-Cell Lymphoma

Pre-Transplant Hypomethylating Agents Do Not Influence Post-Transplant Outcomes in Myelodysplastic Syndrome

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Post Autologous Stem Cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/ VGPR after Induction Therapy

Comparison of Outcomes of Post-Transplant Cyclophosphamide between Haplo-Identical and Matched/Mismatched Donor Peripheral Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only